Response Biomedical Corp. (RPBIF.OB) Reports 69 Percent Increase in Total Revenue
Response Biomedical Corp., a developer and manufacturer of rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications, recently announced that the company recorded total revenue of $9.9 million for 2009, an increase of 69 percent compared to 2008. In addition, revenue for the company’s clinical products jumped 85 percent over 2008 to $6.8 million. For the year ended December 31, 2009, Response Biomedical reported a net loss of $9.5 million, or $0.04 per share, compared to a loss of $13.7 million, or $0.10 per share, in 2008. Details of the company’s complete financial results…